Aims/hypothesis. It has been suggested that uncoupling protein 3 (UCP3) can increase energy expenditure, thereby regulating body weight. Although studies on UCP3 knock-out mice suggest that lack of UCP3 function does not cause obesity or Type 2 diabetes, it is possible that up-regulation of UCP3 function improves these disorders or their clinical sequelae. A 10-to 20-fold increase of UCP3 gene expression is achievable through physiological or pharmacological stimuli. We examined the phenotype of transgenic mice with approximately 18-fold overexpression of mouse UCP3 mRNA in skeletal muscle. Methods. We generated transgenic mice with approximately 18-fold overexpression of mouse UCP3 mRNA in skeletal muscle under control of the skeletal muscle-specific muscle creatine kinase gene promoter. The phenotype of these mice was analysed either on a standard diet or on a 4-week high-fat diet.
Uncoupling protein 3 (UCP3), which has been identified by several groups [1, 2, 3, 4] , is reported to be involved in energy metabolism by uncoupling electron transport from ATP synthesis in mitochondria and is expressed at high levels in the skeletal muscle [3] , an important organ in glucose and lipid metabolism [5] . Uncoupling protein 3 mRNA is expressed at much higher levels than uncoupling protein 2 (UCP2) mRNA in the skeletal muscle in vivo although accurate comparison is difficult [1, 2, 3, 4] . As uncoupling protein 1 (UCP1) gene expression is almost undetectable in the skeletal muscle [6] , UCP3 is considered to be the most relevant UCP in the skeletal muscle. Several studies have reported that UCP3 gene expression is up-regulated by triiodothyronine, catecholamines, fatty acids and peroxisome-proliferator-activated receptor (PPAR) agonists [4, 7, 8, 9] .
It has been suggested that UCP3 is involved in energy expenditure, possibly leading to regulation of body weight. In two studies on UCP3 knock-out mice [10, 11] there was no difference between UCP3 knock-out and wild-type mice with regard to obesity, body temperature and serum concentrations of insulin, glucose, triglycerides and fatty acids. No obvious phenotype of UCP3 knock-out mice was observed when comparing their responses to fasting, exposure to cold, a high-fat diet and treatment with thyroid hormones with those of the control mice. This suggests that lack of UCP3 is not a major determinant of energy expenditure and obesity.
Although loss of the UCP3 function does not cause obesity or Type 2 diabetes, it is still possible that up-regulation of the UCP3 function improves these disorders. One study reported that glucose transport and GLUT4 translocation to the cell surface were increased in L6 myotubes in which UCP3 was overexpressed in vitro by adenovirus-mediated gene transfer [12] . Another study reported that transgenic mice overexpressing human UCP3 in the skeletal muscle weighed approximately 30% less than their wild-type littermates and that these transgenic mice were insulin-sensitive, with lower fasting plasma glucose and insulin concentrations [13] . These data suggest that drugs increasing UCP3 could have anti-obesity and/or antidiabetic effects. However, the levels of UCP3 overexpression in this study were very high (approximately 66-fold at the mRNA level), and no known stimulus will increase UCP3 gene expression by that amount. Several reports noted that UCP3 gene expression increased by a maximum of 10-to 20-fold in response to physiological or pharmacological stimuli in vivo [14] . We have reported that an agonist for PPARδ increased UCP3 gene expression by approximately 20-fold using L6 myotubes in vitro [15] . In this context we produced transgenic mice that overexpress mouse UCP3 mRNA in the skeletal muscle by approximately 18-fold. Furthermore, to explain the effect of the increased UCP3 on diet-induced obesity, we examined the phenotype of transgenic mice on high-fat diet.
Materials and methods
Generation of transgenic mice overexpressing UCP3. Based on the non-coding sequence of rat UCP3 cDNA [3] , sense and antisense primers (sense: 5′-CAA AGG AAC CAG GCC ATC CTC CGG AAC C-3′; antisense: 5′-AA AGT ACC AAG CGG CCT GCT TGC CTT GT-3′) were prepared. Reverse transcription-PCR was done using Superscript (Invitrogen, Carlsbad, Calif., USA) with 10 µg of total RNA from mouse gastrocnemius muscle [16] . The PCR products were subcloned and sequenced (Accession ID: AB008216) by the dideoxy method [3] . A fusion gene comprising the mouse muscle creatine kinase (MCK) promoter and mouse UCP3 cDNA coding sequences was designed to enable UCP3 expression to be targeted mainly to the skeletal muscle (Fig. 1a) [17] . The purified Hind III-Sac I fragment (10 µg/ml) was microinjected into the pronucleus of fertilised BDF 1 (DBA2 X C57/B6) mouse eggs (Japan SLC, Hamamatsu, Japan). The viable eggs were transferred into the oviducts of pseudopregnant female ICR mice (Japan CLEA, Osaka, Japan) using standard techniques [18] . Transgenic founder mice were identified by Southern blot analysis of tail DNAs using the mouse UCP3 cDNA fragment as a probe [18] . Transgenic mice were used as heterozygotes. Transgenic mice were back-crossed with C57/B6 mice. Mice of F4 generation or later were used in this study. Animals were housed in a temperature-, humidity-, and light-controlled room (temperature: 22±0.5°C, humidity: 50%, 12-h light, 12-h darkness) with free access to water and food. All experimental procedures were approved by the Kyoto University Graduate School of Medicine Committee on Animal Research and carried out in accordance with the Declaration of Helsinki as revised in 2000. The principles of laboratory animal care (NIH publication no. 85-23, revised 1985); were followed, as well as any specific national laws.
RNA extraction and northern blot analysis. Total RNA was extracted from tissues using Trizol reagent (Invitrogen) as described previously [19] . Filters containing 30 µg of total RNA were prepared. Northern blot analyses were done using cDNA probes of mouse UCP3 [9] . The density of 18S rRNA stained with ethidium bromide was used to monitor the amount of total RNA in each sample.
Western blot analysis. The gastrocnemius muscle was removed and homogenised in ice-cold buffer (50 mmol/l Tris (pH 7.4), 150 mmol/l NaCl, 1% Triton X-100, 1% sodium deoxycholate, and 0.1% SDS) containing 1 mmol/l phenylmethlysulfonyl fluoride, 0.01 mmol/l leupeptin and 5 µg/ml aprotinin. Homogenates were centrifuged and supernatants were used for analysis of total protein. Mitochondrial fraction was obtained from gastrocnemius muscle as described previously [20] . Antibody for rat UCP3, its inhibitory peptide and antibody for human UCP3 were purchased from Alpha Diagnostic International (San Antonio, Tex., USA). Total and mitochondrial protein were used for SDS-PAGE and western blot analyses using antibodies for rat UCP3 or human UCP3 [21] .
Isolation of mitochondria. Mitochondria were isolated from gastrocnemius skeletal muscle (n=7) as described previously [22, 23] . Mice were decapitated before removal of skeletal muscle. The skeletal muscle was homogenised in buffer containing 250 mmol/l sucrose, 1 mmol/l HEPES and 0.2 mmol/l EDTA (pH 7.2 with KOH). Fractionation of the homogenate was achieved by spinning for 10 min at 1500 g and at 4°C. The supernatant was then poured through a 250 µmol/l Nitex screen (Dynamic Aqua-Supply, British Columbia, Canada) and re-spun for 14 min at 16 000 g and at 4 C to obtain a mitochondrial pellet. The pellet was re-suspended on ice in 175 µl of suspension medium containing 120 mmol/l KCl, 20 mmol/l sucrose, 3 mmol/l HEPES, 2 mmol/l MgCl 2 , 2 mmol/l EGTA and 0.5% BSA (pH 7.2 with KOH). Stock 9% BSA was defatted by the Chen method [24] and dialysed against 153 mmol/l NaCl and 11 mmol/l KCl. The protein concentration of the mitochondrial suspension was assayed by the modified Lowry method using BSA as the reference standard. . Western blot analysis (d) using antirat UCP3 antibody. Amounts analysed were: 100 µg of total protein and 600 ng of protein from mitochondrial fraction. No added peptide or inhibitory peptide (to which the antibody was raised) was included during the first antibody incubation. Western blot analysis (e) using human UCP3 antibody. Amounts analysed were: 100 µg of total protein and 600 ng of protein from mitochondrial fraction (0.5 mg protein/ml) were placed in the incubation chamber (incubation temperature: 37°C) and magnetically stirred. Succinate-driven respiration was assessed by using 5 µmol/l rotenone to block complex 1 and 0.4 µg nigericin to assess total protonmotive force through measurements of membrane potential. State 4 respiration (maximum non-phosphorylating or leakdependent respiration) was measured in the presence of saturating amounts of the ATP synthase inhibitor, oligomycin (10 µg/mg protein). Mitochondrial proton leak kinetics were assessed by adding malonate in increments (0.3 mmol/l to 3.6 mmol/l). The respiration rate of muscle mitochondria was measured using a Clark-type oxygen electrode (Hansatech, Norfolk, UK) [22] . Protonmotive force was measured using a methyltriphenylphosphonium-sensitive electrode as described previously [22] .
Measurement of mitochondrial oxygen consumption and mitochondrial protonmotive force (∆p). Mitochondrial suspensions

Measurements of body weight and cumulative food intake.
Body weight was measured daily, beginning at 4 weeks of age. Food intake was measured daily over a 1-week period at the age of 26 weeks. It was measured in male mice, which were maintained in individual metabolic cages.
Measurement of oxygen consumption. The gas analyser used to assess the metabolic rate consisted of six acrylic metabolic chambers, CO 2 and O 2 analysers (RL-600, AlcoSystem, Tokyo, Japan), and a switching system (ANI6-A-S, AlcoSystem) to sample gas from each metabolic chamber. Each metabolic chamber had 125.4 cm 2 floor space and was 6.5 cm in height. Oxygen consumption was calculated by measuring the O 2 and CO 2 concentrations of each chamber [25] .
Glucose and insulin tolerance tests. For the glucose tolerance test 20-week-old transgenic mice and their non-transgenic littermates were treated with an intraperitoneal injection of 2.0 mg/g glucose after an overnight fast [18] . For the insulin tolerance test, mice were injected intraperitoneally with 0.5 mU/g human regular insulin (Novolin R, Novo Nordisk, Bagsvard, Denmark) [18] . Blood samples were taken from the mouse tail vein before and 30, 60 and 90 min after the injection. Plasma glucose concentrations were measured by the glucose oxidase method with a reflectance glucometer (One Touch II, Lifescan, Milpitas, Calif., USA).
High-fat diet study. To examine the effect of UCP3 overexpression on diet-induced obesity, UCP3 transgenic mice and nontransgenic littermates were fed a high-fat diet for 4 weeks from 24 weeks of age. The high-fat diet was produced by Oriental Bioservice (Kyoto, Japan) [26] . Its fat content was 23%, whereas that of standard chow was 7%.
Histology. We did histological examinations of skeletal muscle, white and brown adipose tissues, heart, liver, and pancreas. This was done by light microscopy, using 5-µm-thick sections from 10% buffered, formalin-fixed, paraffin-embedded specimens which were stained with hematoxylin and eosin [18] .
Measurement of plasma concentrations of glucose, triglyceride, fatty acids, cholesterol and insulin.
Blood samples were taken from the retro-orbital sinus of mice at 9:00 hours after overnight fasting or at 14:00 hours. Plasma glucose, triglyceride, and insulin concentrations were measured by the glucose oxidase method with a reflectance glucometer, the enzymatic kit (Wako Pure Chemical, Osaka, Japan) and by RIA with mouse insulin standards (Morinaga BioLab, Yokohama, Japan), respectively [18] .
Statistical analysis. Data were expressed as means ± SE. Statistical significance was tested by one-way ANOVA. If F was found to be significant, the Student's t test was used to test individual differences. A p value of less than 0.05 was considered statistically significant.
Results
Generation of transgenic mice overexpressing UCP3.
A fusion gene comprising the mouse MCK promoter and mouse UCP3 cDNA coding sequence was designed to enable UCP3 expression to be targeted to the skeletal muscle (Fig. 1a) . Several transgenic lines with different copy numbers of the transgene were obtained. With the mouse UCP3 cDNA probe, northern blot analysis showed that an mRNA species of 2.4 kb in size, which was expected from the fusion gene of MCK promoter and mouse UCP3 cDNA, was expressed abundantly in the skeletal muscle from several lines of the transgenic mice (Fig. 1b) . The highest UCP3 mRNA levels were obtained in Line A of the transgenic lines and were approximately 18-fold higher than in non-transgenic littermates (Fig. 1b,c) . The second highest mRNA levels were approximately 15-fold higher (Line B; Fig. 1b) .
Western blot analysis of protein expression in the skeletal muscle of these two lines detected multiple bands, separated by electrophoresis, of total protein extracted from the skeletal muscle (Fig. 1d) . When protein of mitochondrial fraction was electrophoresed, antirat UCP3 antibody detected, as expected from the molecular mass of mouse UCP3, a single band near 34 M r (Fig. 1d) . This band at 34 M r disappeared when inhibitory peptide was simultaneously incubated (Fig. 1d) . Similar results were obtained using antihuman UCP3 antibody (Fig. 1e) .
To quantify UCP3 concentrations in the skeletal muscle of transgenic mice, we examined transgenic mice of Line A. Western blot analyses were done using various amounts of protein from skeletal muscle mitochondria. Figure 2a is a representative result. It shows that the density of bands of 600 ng of protein from a UCP3 transgenic mouse was nearly equivalent to that of 10 µg of protein from a non-transgenic littermate. UCP3 protein was approximately 15 times higher in transgenic mice than in nontrasgenic littermates (n=5; Fig. 2b ). As the MCK promoter also induces gene expression in the cardiac muscle, we examined the UCP3 gene expression there, finding that UCP3 mRNA levels were slightly higher in the cardiac muscle of Line A and Line B than in those of nontransgenic littermates. In Line A and Line B, UCP3 mRNA levels in the cardiac muscle were less than 1% of those in the skeletal muscle. UCP3 protein levels were not detected in the cardiac muscle either of transgenic mice or of non-transgenic littermates. UCP3 mRNA levels in the brown adipose tissue of transgenic mice were not significantly different from those of non-transgenic littermates (107±12% in Line A and 112±9% in Line B, p>0.05). Northern blot analysis with 30 µg of total RNA failed to detect any band of UCP3 mRNA in tissues of transgenic mice other than skeletal muscle, cardiac muscle and brown adipose tissue. The transgenic mice of both lines were fertile, and viable throughout adulthood with no appreciable complications. All these results were observed in transgenic mice of each sex.
Mitochondrial proton leak. The kinetic response curve for the proton leak reactions showed trends towards increased mitochondrial oxygen consumption over a range of values for ∆p (Fig. 3) . The absolute values for oxygen consumption and ∆p at State 4 (the point on each curve at the furthermost point on the right) were not statistically different between groups (Fig. 3) (Table 1) . In glucose and insulin tolerance tests on 28-week-old transgenic mice and non-transgenic littermates no significant differences were noted (Fig. 5a, Fig. 6a ). As the phenotype described above was noted in transgenic mice of Line A and Line B, we used Line A, the line expressing the highest levels of UCP3, for further examination.
Body weight of transgenic mice on high-fat diet. One week after beginning the high-fat diet, the transgenic mice were approximately 10% less obese than the non-transgenic littermates (28.3±0.6 g vs 31.6±0.8 g, p<0.05; Fig. 4 ). After 4 weeks of a high-fat diet, the transgenic mice were approximately 14% less obese than the non-transgenic littermates (32.4±1.3 g vs 37.5±1.3 g, p<0.05; Fig. 4 Data are means ± SE (n=5 to 7) Fig. 5a , b. Glucose tolerance test in (a) male 28-week-old transgenic mice and non-transgenic littermates on a standard chow diet and (b) in male 28-week-old transgenic mice and non-transgenic littermates after 4 weeks on a high-fat diet. Data are expressed as means ± SE (n=7 to 9). *p<0.05 vs nontransgenic littermates Data are expressed as means ± SE (n=7 to 9). *p<0.05 vs nontransgenic littermates
